Recent research comes from a switch study for tenofovir alafenamide (TAF), a new version of tenofovir, which showed a 2% improvement in bone density for those taking the new form of the drug.
Liz Highleyman, editor-in-chief of HIVandHepatitis.com, spoke with Jürgen Rockstroh, M.D., Kenneth Sherman, M.D., Ph.D., and Dost Sarpel, M.D., about the latest research on the treatment of hepatitis B and C.
Three studies offer reassuring news that adverse kidney changes that accompany Truvada use for PrEP are rarely serious and universally reverse after stopping the medication, but also that older people and those with the best adherence might need to b...
"Current CDC guidelines may miss a significant number of asymptomatic STIs among PrEP users," researchers concluded, suggesting that STI screening may be warranted at each three-monthly visit.
Research presented at CROI 2016 shows that Truvada PrEP is safe for most people, but impaired kidney function -- usually mild or moderate -- may occur in a small proportion of people on PrEP, especially if they have other risk factors.
A cardiovascular risk-scoring system known as ASCVD appears to be a better predictor of myocardial infarction (MI) among people with HIV than other risk scores, including Framingham and D:A:D, according to new research.
While the total number of gut bacteria doesn't differ between HIV-negative and HIV-positive people, the composition of the microorganisms changes with HIV infection, according to research presented at CROI 2016.
With buildings leveled by arson and systematic neglect, its population crammed into debilitated and overcrowded housing without access to basic public safety and public health services, the inescapable poverty of the Bronx provided fertile ground for...
Flu season can bring anxiety for people living with HIV and their health care providers. But do HIV-positive people have more severe symptoms of flu than people who are not living with HIV? In this interview, Christina Schofield, M.D., shares her stu...
HIV treatment as prevention has become a well-known and powerful tool in the global HIV response. In this interview, Mark Sulkowski, M.D., discusses whether a similar approach could be used in the prevention of hepatitis C.